复方浙贝颗粒配方伍用化疗治疗难治性急性白血病临床研究

目的:观察复方浙贝颗粒配方配合化疗治疗难治性急性白血病的临床疗效。方法:采用随机、双盲、多家医院的病例对照研究方法,将126例难治性急性白血病患者分两组,治疗组65例,用复方浙贝颗粒配方与常规化疗方案合用;对照组61例,服用安慰剂(麦芽颗粒),1疗程结束后进行临床疗效判断。结果:治疗组的完全缓解率(40.0%)与总有效率(72.3%)均优于对照组(24.6%和52.5%)。结论:复方浙贝颗粒配方与常规化疗方案伍用,可增强化疗药物对白血病细胞的杀伤作用,提高临床缓解率,且具有较好的临床用药安全性。     

胃癌中医证素探讨

通过文献研究与临床实践提取对胃癌基本证素认识,并结合古今临证经验,应用证候要素概念分析胃癌中医发病特点,总结胃癌基本证候要素与疾病的动态演变规律,提出了"胃内寒、脾气虚为胃癌本虚证素;食、痰、瘀、毒、气滞、内湿、内火为胃癌标实证素;胃阴亏虚、气血俱虚、脾肾阳虚为胃癌病理结局证素"的学术观点。     

复方浙贝颗粒对阿霉素导致肿瘤模型小鼠心肝肾检测指标影响的研究

目的研究复方浙贝颗粒对阿霉素导致肿瘤动物模型小鼠心肝肾功能的影响。方法建立小鼠淋巴细胞、白血病细胞(P388)移植瘤模型后,将70只造模成功的昆明小鼠随机分为生理盐水对照组、ADM常规剂量组、CZBG组、CZBG联合ADM大剂量组、CZBG联合ADM常规剂量组、CZBG联合ADM小剂量组、CZBG联合ADM极低剂量组,每组各10只小鼠。实验结束后处死小鼠,心脏采血并离心,提取上层血清,用全自动日立生化仪7080检测LDH、ALT、AST、Cr、BUN变化,以判定对心肝肾的影响。结果 (1)实验各组LDH、ALT、AST、Cr数值比较,无统计学意义(P0.05);(2)实验各组BUN数值比较,生理盐水对照组分别与ADM常规剂量组、CZBG联合ADM大剂量组、CZBG联合ADM常规剂量组、CZBG联合ADM小剂量组、CZBG联合ADM极低剂量组比较,差异均有统计学意义(P0.05);CZBG组分别与CZBG联合ADM大剂量组、CZBG联合ADM常规剂量组、CZBG联合ADM小剂量组、CZBG联合ADM极低剂量组比较,差异均有统计学意义(P0.05);ADM常规剂量组分别与CZBG联合ADM大剂量组、CZBG联合ADM常规剂量组比较,差异均有统计学意义(P0.05)。结论 CZBG没有明显舒缓ADM导致的肿瘤模型小鼠心、肝功能的损害效应,但与ADM联合应用在具有增敏提高ADM的肿瘤抑制率效应同时,不会增加ADM的毒性反应。     

Clinical Research of Compound Zhebei Granules for Increasing the Therapeutic Effect of Chemotherapy in Refractory Acute Leukemia Patients

Objective： To observe the effects of Compound Zhebei Granules （复方浙贝颗粒 CZG） in chemotherapy for refractory acute leukemia. Method： Using a randomized, double-blind and multi-central concurrent control clinical research project, the patients conformed with the diagnostic criteria, according to the drug randomized method, were divided into a CZG group and a control group. The patients of the two groups respectively took the observation drug or a placebo 3 days before chemotherapy, and the therapeutic effects were evaluated after one course of chemotherapy. According to the clinical research project, 137 patients were enrolled, including 71 cases in the CZG group and 66 cases in the control group. Results： The clinical complete remission （CR） rate was 42.3% in the CZG group with a total effective rate of 73.2%, and it was 25.8% in the control group with a total effective rate of 53.0%, showing a statistically significant difference between the two groups （P〈0.05）. Conclusion： CZG can increase the clinical remission rate for refractory acute leukemia during chemotherapy.     

胃癌中医证素探讨

通过文献研究与临床实践提取对胃癌基本证素认识,并结合古今临证经验,应用证候要素概念分析胃癌中医发病特点,总结胃癌基本证候要素与疾病的动态演变规律,提出了"胃内寒、脾气虚为胃癌本虚证素;食、痰、瘀、毒、气滞、内湿、内火为胃癌标实证素;胃阴亏虚、气血俱虚、脾肾阳虚为胃癌病理结局证素"的学术观点.